Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

MJPharma ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading... Loading... Loading... Loading...

1000.0 Bankruptcy Risk  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   17.7% 19.7% 10.3% 9.6% 13.8% 18.5% 23.3% 23.3%   Credit score (0-100)   11 7 25 27 16 7 3 3   Credit rating   B B BB BB BB B B B   Credit limit (kDKK)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Net sales   0 0 118 39 8 16 16 16   Gross profit   419 39.4 105 28.1 0.6 9.0 0.0 0.0   EBITDA   90.5 14.4 92.2 16.0 0.1 4.2 0.0 0.0   EBIT   90.5 14.4 92.2 16.0 0.1 4.2 0.0 0.0   Pre-tax profit (PTP)   90.9 14.2 92.2 16.0 -0.0 3.9 0.0 0.0   Net earnings   70.3 11.2 71.9 12.4 -0.0 3.0 0.0 0.0   Pre-tax profit without non-rec. items   90.9 14.2 92.2 16.0 -0.0 3.9 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Tangible assets total   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Shareholders equity total   120 61.2 122 62.4 50.0 53.0 3.0 3.0   Interest-bearing liabilities   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   188 67.2 157 73.0 56.0 59.7 3.0 3.0   Net Debt   -188 -62.8 -115 -57.8 -48.3 -54.5 -3.0 -3.0     See the entire balance sheet 1000.0 Volume  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Net sales   0 0 118 39 8 16 16 16   Net sales growth   0.0% 0.0% 0.0% -66.8% -80.0% 108.3% 0.0% 0.0%   Gross profit   419 39.4 105 28.1 0.6 9.0 0.0 0.0   Gross profit growth   0.0% -90.6% 165.6% -73.2% -98.0% 1,516.4% -100.0% 0.0%   Employees   0 0 0 0 0 0 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   188 67 157 73 56 60 3 3   Balance sheet change%   0.0% -64.2% 134.0% -53.6% -23.4% 6.7% -95.0% 0.0%   Added value   90.5 14.4 92.2 16.0 0.1 4.2 0.0 0.0   Added value %   0.0% 0.0% 78.4% 40.9% 0.7% 25.9% 0.0% 0.0%   Investments   0 0 0 0 0 0 0 0   Net sales trend   0.0 0.0 0.0 -1.0 -2.0 1.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A EBITDA %   0.0% 0.0% 78.4% 40.9% 0.7% 25.9% 0.0% 0.0%   EBIT %   0.0% 0.0% 78.4% 40.9% 0.7% 25.9% 0.0% 0.0%   EBIT to gross profit (%)   21.6% 36.5% 88.1% 56.8% 9.9% 47.0% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 61.2% 31.9% -0.4% 18.5% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 61.2% 31.9% -0.4% 18.5% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 78.4% 40.9% -0.4% 23.7% 0.0% 0.0%   ROA %   48.5% 11.3% 82.1% 13.9% 0.1% 7.3% 0.0% 0.0%   ROI %   75.6% 15.9% 100.7% 17.3% 0.1% 8.2% 0.0% 0.0%   ROE %   58.4% 12.3% 78.5% 13.5% -0.1% 5.8% 0.0% 0.0%   1000.0 Solidity  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Equity ratio %   64.1% 91.1% 77.5% 85.5% 89.3% 88.7% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 30.1% 27.1% 76.9% 41.6% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% -67.3% -121.0% -542.1% -294.0% -18.3% -18.3%   Net int. bear. debt to EBITDA, %   -207.4% -436.3% -124.2% -362.1% -87,781.8% -1,294.4% 0.0% 0.0%   Gearing %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Liquidity  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Quick Ratio   2.8 11.2 4.4 6.9 9.3 8.8 0.0 0.0   Current Ratio   2.8 11.2 4.4 6.9 9.3 8.8 0.0 0.0   Cash and cash equivalent   187.6 62.8 114.5 57.8 48.3 54.5 0.0 0.0   1000.0 Capital use efficiency  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Trade debtors turnover (days)   0.0 0.0 132.7 119.3 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 137.8 353.5 302.2 338.8 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 133.8% 187.2% 717.5% 367.5% 18.3% 18.3%   Net working capital   120.3 61.2 121.9 62.4 50.0 53.0 0.0 0.0   Net working capital %   0.0% 0.0% 103.7% 160.1% 640.6% 326.0% 0.0% 0.0%   1000.0 Employee efficiency  2016 2016/12 2017 2017/12 2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022e N/A 2023e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   0 0 0 0 0 0 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   0 0 0 0 0 0 0 0   EBIT / employee   0 0 0 0 0 0 0 0   Net earnings / employee   0 0 0 0 0 0 0 0